EZZ Life Science Holdings Ltd. ( (AU:EZZ) ) just unveiled an update.
EZZ Life Science Holdings Limited reported strong operational performance for the quarter ending March 31, 2025, despite a decline in customer receipts due to seasonal factors and reduced digital advertising. The company achieved a positive cash inflow of $1.5 million and maintained a record cash reserve of $21.1 million. EZZ launched two new products and upgraded three existing ones, enhancing its competitive position. The company expanded its domestic distribution and made strategic progress in entering the US market. EZZ also increased brand visibility through sponsorships and strengthened its presence in China, positioning itself for long-term growth.
More about EZZ Life Science Holdings Ltd.
EZZ Life Science Holdings Limited is a genomic life science company focused on improving quality of life and human health through the development and distribution of high-quality consumer health products. The company operates across Australia, New Zealand, China, and globally, utilizing omnichannel models to reach its market.
YTD Price Performance: -48.57%
Average Trading Volume: 60,143
Technical Sentiment Signal: Hold
Current Market Cap: A$74.53M
Find detailed analytics on EZZ stock on TipRanks’ Stock Analysis page.